Gastric cancer - clinical and epidemiological aspects
Gastric cancer - clinical and epidemiological aspects
复制标题
DOI：
10.1111/hel.12339
复制
发表时间：
2016-09-01
期刊：
影响因子：
4.4
通讯作者：
Malfertheiner, Peter
中科院分区：
文献类型：
--
作者：
Venerito, Marino;Link, Alexander;Malfertheiner, Peter
胃癌（GC）在癌症发病率中排名第五，在癌症死亡率中排名第二。流行病学资料显示，霍奇金淋巴瘤幸存者和与自身免疫性胃炎病因相关的恶性贫血患者发生胃癌的风险增加。通过胃蛋白酶原（PG） I和PG I/II筛查自身免疫性甲状腺疾病患者，4例患者中有1例发现自身免疫性胃炎伴氧合性胃萎缩，可推荐用于预防胃癌。国际癌症研究机构报告说，食用加工肉类与胃癌风险增加之间存在正相关关系。一种基于生物标志物、年龄、性别、吸烟状况、胃癌家族史和高盐食品消费的胃癌风险预测模型显示出良好的预测效果，可能会提示个人改变生活习惯，定期检查或参加筛查项目。基于与临床病理特征相关的原发性切除癌基因表达的新型GC分类。用于GC筛选的非编码RNA仍然是多个研究的焦点。内镜切除的早期胃癌患者比手术患者更容易发生异时性病变，因此在这个特殊的队列中需要内镜监测。在化疗的基础上增加胃切除术并没有提高晚期胃癌患者的生存率和单一的不可治愈因素。阿帕替尼（Apatinib）是一种新型口服血管内皮生长因子受体2酪氨酸激酶抑制剂，可提高晚期胃癌和进展性疾病患者在既往化疗2线或以上近3个月后的中位总生存期。
Gastric cancer (GC) ranks fifth for cancer incidence and second for cancer deaths. Epidemiological data showed that survivors of Hodgkin's lymphoma and patients with pernicious anemia etiologically linked to autoimmune gastritis are at increased risk of GC. Screening of patients with autoimmune thyroid disease by means of pepsinogen (PG) I and PG I/II detected autoimmune gastritis with oxyntic gastric atrophy in one of four patients and may be recommended for GC prevention purposes. The International Agency for Research on Cancer reported a positive association between consumption of processed meet and increased GC risk. A new GC risk prediction model based on biological markers, age, gender, smoking status, family history of GC, and consumption of highly salted food showed good predictive performance, and might prompt individuals to modify their lifestyle habits, attend regular check-up visits or participate in screening programs. A novel GC classification based on gene expression of primary resected cancers correlated with clinicopathological features. Noncoding RNA for GC screening remains the focus of multiple studies. Patients with early GC undergoing endoscopic resection are more likely to develop metachronous lesions than patients undergoing surgery and endoscopic surveillance is warranted in this special cohort. The addition of gastrectomy to chemotherapy did not improve survival of patients with advanced GC and a single noncurable factor. Apatinib, a novel oral vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, improved the median overall survival of patients with advanced GC and progressive disease after two or more lines of prior chemotherapy of nearly 3months.